cas12206-sup-0001-FigureS1.jpgimage/jpg30KFig. S1. Bone morphogenetic protein-6 (BMP-6) induces androgen hypersensitivity in a human prostate cancer cell line.
cas12206-sup-0002-FigureS2.jpgimage/jpg49KFig. S2. Bone morphogenetic protein-6-mediated androgen hypersensitivity in LNCaP cells.
cas12206-sup-0003-FigureS3.jpgimage/jpg58KFig. S3. Bone morphogenetic protein-6-mediated androgen hypersensitivity in LNCaP cells requires macrophage-derived interleukin-6 (IL-6). AR, androgen receptor; PTHrP, parathyroid hormone-related protein.
cas12206-sup-0004-FigureS4.jpgimage/jpg48KFig. S4. Generation of Tramp-C1 and PTENCaP8 cells with tetracycline-inducible expression of bone morphogenetic protein-6 using the lentivirus-based approach. AR, androgen receptor.
cas12206-sup-0005-FigureS5.jpgimage/jpg66KFig. S5. Macrophage depletion in Tramp-C1/BMP6 tumors. Doxy, doxycycline.
cas12206-sup-0006-FigureS6.jpgimage/jpg62KFig. S6. Macrophage depletion in PTENCaP8/BMP6 tumors. Doxy, doxycycline.
cas12206-sup-0007-TableS1.docWord document24KTable S1. Polymerase chain reaction primer sequences used in this study.

Please note: Wiley Blackwell is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.